drugset / Trial / NCT03646721
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
Timeline
- Start
- 2018-08-29
- Primary completion
- 2020-05-07
- Completion
- 2020-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-1241 | Unknown | 25 mg | — |
| Subject | DA-1241 | Unknown | 50 mg | — |
| Subject | DA-1241 | Unknown | 100 mg | — |
| Subject | DA-1241 | Unknown | 200 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |